Arrivent BioPharma, Inc. (AVBP)
16.48
+0.02
(+0.12%)
USD |
NASDAQ |
Oct 13, 10:40
Arrivent BioPharma Debt to Equity Ratio : 0.001 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.001 |
| March 31, 2026 | 0.0013 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.0002 |
| June 30, 2025 | 0.0004 |
| March 31, 2025 | 0.0007 |
| December 31, 2024 | 0.0007 |
| September 30, 2024 | 0.0008 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.0008 |
| March 31, 2024 | 0.0009 |
| December 31, 2023 | 0.0021 |
| September 30, 2023 | 0.0003 |
| June 30, 2023 | 0.0004 |
| March 31, 2023 | |
| December 31, 2022 | 0.0008 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 394.72M |
| Total Liabilities (Quarterly) | 27.88M |
| Shareholders Equity (Quarterly) | 366.84M |
| Current Ratio | 14.16 |
| Net Debt Paydown Yield | 0.00% |